Effect Of S-1Combined With The Weekly Administration Of Liposome-paclitaxel As First-line Chemotherapy On Advanced Gastric Cancer

Objective: This study is aimed to assess the efficacy and toxicity of S-1and weeklyliposome–paclitaxel combination therapy as frst-line treatment for advanced gastriccancer.Methods: The chemotherapy regime was S-160mg (body surface area1.5) or50mg(1.25, body surface area,1.5) twice a day on days1–28, combined with80mg/m2liposome–paclitaxel given on days1,8,15and22,6weeks as one cycle. Treatmentwas continued until progressive disease or intolerable toxicity occurred. The response rate,progression-free survival (PFS), overall survival (OS) and toxicity were evaluated after2cycles.Results: A total of26patients were enrolled, and the median age was53years (range＝28–70years;16males and10females). The response rate and disease control rate were34.6%（9/26）and88.5%(23/26), respectively. The median PFS was6.0months, and themedian OS was10.0months. The main treatment related toxicities were hematologicaltoxicity，fatigue，and gastrointestinal reaction. Grade III～IV toxicity included neutropenia(7.7%)，nausea and vomiting(3.9%)and diarrhea(3.9%).Conclusions: The weekly administration of a combined regimen of liposome–paclitaxel plus S-1is effective and has a favorable toxicity profle as frst-line treatment foradvanced gastric cancer.